These results, together with a past report showing that a little-molecule ACKR3 agonist CCX771 reveals anxiolytic-like actions in mice,2 support the strategy of focusing on ACKR3 as a unique method to modulate the opioid program, which could open new therapeutic avenues for opioid-similar Conditions.At that time, Microsoft Advertising will make use